Pharmacogenetic research of individual differences in the occurrence of Paroxetine discontinuation syndrome.

帕罗西汀是一种选择性血清素再摄取抑制剂（SSRI），目前已成为治疗抑郁症和焦虑症的一线药物。然而，突然停药或减少SSRIs剂量后的停药综合征最近已被证实。目前尚无关于SSRI停药综合征与基因多态性关系的研究。在这项研究中，我们研究了血清素相关基因多态性对帕罗西汀停药综合征发生的影响。综上所述，突然停药是帕罗西汀停药综合征发生的主要危险因素。此外，5-HT1A受体基因的C(-1019)G多态性可能与帕罗西汀停药综合征的发生有关。

Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has now become the first-line treatment for depression and anxiety disorder. However, discontinuation syndrome following abrupt withdrawal or dose reduction of SSRIs has been recently documented. There are no studies with regard to assess the relation of SSRI discontinuation syndrome and gene polymorphisms. In this study, we investigated the effect of the serotonin-related genetic polymorphisms on the occurrence of paroxetine discontinuation syndrome. In conclusion, the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome. In addition, the C(-1019)G polymorphism of the 5-HT1A receptor gene may be related to the occurrence of paroxetine discontinuation syndrome.